Soleno Therapeutics (SLNO) EBITDA Margin (2015 - 2026)

Soleno Therapeutics' (SLNO) quarterly EBITDA Margin came in at 33.06% in Q1 2026, down 23.37% on a QoQ basis from 43.15% in Q4 2025.

Soleno Therapeutics (SLNO) EBITDA Margin (2015 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 5 years of EBITDA Margin data on file, last reported at 33.06% in Q1 2026.

On a quarterly basis, EBITDA Margin changed N/A year-over-year to 33.06% in Q1 2026; TTM through Mar 2026 was 30.33%, a N/A change from a year earlier, with the FY2025 full-year figure at 4.94%, changed N/A from the prior year.
EBITDA Margin for Q1 2026 stood at 33.06%, down from 43.15% in the prior quarter.
Over the last five years, EBITDA Margin for SLNO reached as high as 43.15% in Q4 2025 and fell as low as 19.98% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	16.51%
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	17.83%
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	30.35%
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Soleno Therapeutics	874.25 Mn	618.67 Mn	93.41 Mn	33.06%

Download Data